Investment Pitches

Pitch Summary:
Guidewire is a market leader in next-generation property and casualty (P&C) insurance software. A few years ago, Guidewire transitioned from a licensed software business model to a subscription-based cloud service. Historically, as companies emerge from these (often messy) transitions, their profit growth tends to accelerate. We believe Guidewire is at this inflection point. The company has consistently performed in line with our thesis, driving a durable and compelling profit cycle. While we remain optimistic about Guidewire’s growth prospects, we have been reducing our position due to the company's increasing market capitalization, which is approaching the upper limits of our small-cap mandate.

BSD Analysis:
Guidewire’s successful cloud transition positions it for accelerating subscription revenue, expanding margins and stronger free-cash-flow conversion. As the P&C industry modernizes, Guidewire holds a dominant competitive position with high switching costs. While valuation has risen with market-cap growth, fundamentals support continued compounding. Key risks include long enterprise sales cycles.

Pitch Summary:
Stevanato is a leading provider of specialty glass and plastic packaging to the health care industry, as well as the leading machinery supplier to glass vial makers and fill and finish facilities. We believe a mix shift from bulk products to higher margin sterilized products and the overall growth of biologic drugs will drive attractive earnings growth. We increased our position as we gained greater confidence that the worst of the COVID-related inventory overstocking challenges had passed. Moving forward, we believe the company's and industry's profit cycle drivers are more likely to demonstrate the durable growth characteristics that originally attracted us to this stock.

BSD Analysis:
Stevanato stands to benefit from structural growth in biologics and a mix shift toward high-margin sterile packaging, supporting multi-year EBITDA expansion. Inventory normalization removes a key overhang, and valuation remains attractive versus global life-science tools peers. Key risks include customer concentration and regulatory delays.

Pitch Summary:
ServiceTitan is the leading vertical software provider for the trades (e.g., plumbing, HVAC, electrical), an area that has historically been underserved by technology. The company is focused on residential and commercial services that manage the full workflow—from lead generation to payment. Revenue comes from subscriptions and usage-based payment processing. We see multiple opportunities for growth, including acquiring new customers, upselling existing customers and expanding into more trades. ServiceTitan has been delivering in line with our thesis, particularly during its initial quarters as a public company amid a highly uncertain market environment. We took advantage of stock weakness following a secondary issuance after the IPO lockup to increase our position from the GardenSM to the CropSM.

BSD Analysis:
ServiceTitan’s vertical-software dominance gives it strong pricing power and long-term ARR visibility. Expansion into adjacent trades and payments monetization enhances LTV/CAC. Shares remain expensive versus horizontal SaaS peers, but growth durability and operating leverage warrant the premium. Key risks include execution on scaling enterprise features.

Pitch Summary:
Birkenstock is a heritage casual footwear brand known for its portfolio of primarily open-toe and open-heel products. It operates a hybrid distribution model across both wholesale and direct-to-consumer channels and executes a supply-constrained strategy that drives high levels of full-price sell-through. This disciplined approach has historically supported measured and sustainable growth. We believe the brand’s enduring franchise value and supply-led model position it well for steady unit expansion and rising average selling prices—together driving attractive long-term revenue growth. We initiated a GardenSM position in Birkenstock toward the end of Q1 2025, as the stock weakened in anticipation of potential tariff impacts and an increasingly uncertain consumer spending environment. We continued to build our position during the “Liberation Day” selloff, as we believe there is a durable set of company-specific profit cycle drivers, including product cycle innovation, increasing geographic distribution and a time- and cyclical-tested brand.

BSD Analysis:
Birkenstock’s supply-led model supports strong gross margins and consistent ASP expansion, while brand durability enables resilient demand even through macro volatility. The company trades at a consumer-discretionary multiple that could rerate higher as DTC mix rises. Key catalysts include product innovation, global expansion and tighter supply discipline. Risks include tariff exposure and consumer softness.

Pitch Summary:
Madrigal Pharmaceuticals is a commercial-stage biotechnology company focused on treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Madrigal’s lead drug, RezdiffraTM, is the first and only FDA-approved medication to target liver fibrosis, demonstrating high efficacy with minimal side effects. Given the significant failure rates of previous treatments for this condition, we are confident in the company's ability to maintain a competitive edge and further differentiate itself in the market. Additionally, there is potential to expand its application to more advanced stages of liver fibrosis.

BSD Analysis:
Madrigal’s leadership in MASH positions it for rapid revenue scaling as the first approved therapy in a massive underserved market. Rezdiffra’s efficacy profile supports significant pricing power and potential label expansion. While the valuation is elevated, biotech comps suggest further upside if early launch metrics exceed expectations. Key risks include reimbursement dynamics and competitive entrants.

Pitch Summary:
Wingstop, a quick-service restaurant franchisor specializing in fresh, made-to-order chicken wings, sandwiches and sides, is a stock we have owned before and harvested due to our valuation discipline. It is in the early stages of expanding both domestically and internationally, supported by favorable franchisee economics and growing brand awareness. After a few consecutive quarters of same-store sales missing heightened expectations, the stock was overly punished. This created a compelling opportunity for us to reinvest in a highly unique franchise with a solid long-term profit cycle growth profile, not only from domestic and international restaurant openings but also from menu innovation, national branding, partnerships with delivery providers and a value-focused bundling strategy that continues to resonate with customers.

BSD Analysis:
Wingstop’s franchise model drives high returns on capital, and recent share-price weakness created a more attractive entry relative to its long-term mid-teens unit growth outlook. Digital ordering, menu innovation, and international expansion support durable same-store growth. The business commands a premium multiple, but strong free cash flow and brand momentum justify bullish expectations. Risks include chicken wing cost volatility.

Pitch Summary:
Notable buys in the quarter included BWX Technologies. BWX Technologies designs and manufactures nuclear reactor vessels and components for the US Navy and commercial markets. It has the only Nuclear Regulatory Commission Category 1-licensed facilities permitted to handle, store and process highly enriched uranium in the US. This exclusivity gives it a dominant position across both business segments. It maintains a monopoly on nuclear reactors and fuel for US submarines and aircraft carriers, and it offers a differentiated portfolio of heavy nuclear components. The build schedule for US Navy submarines and aircraft carriers provides long-term visible growth, which we expect to be enhanced by upcoming investments by Canada into refurbishing, expanding and building nuclear power plants. In addition, the Trump administration’s stated desire to accelerate US nuclear energy development could become a catalyst for growth.

BSD Analysis:
BWXT is a structurally advantaged defense-nuclear supplier with monopoly positions that provide multi-year revenue visibility and high barriers to entry. Its NRC Category-1 facilities and locked-in Navy build schedules underpin strong backlog and margin durability. The commercial nuclear renaissance and potential policy catalysts add optional upside. While BWXT trades at a premium defense-multiple, its predictable free cash flow and strategic importance justify the valuation.

Pitch Summary:
Clearwater provides automated investment accounting, compliance and risk reporting for insurance companies, corporations and asset managers. Its key differentiator is a master security identifier list that consolidates data from multiple sources, driving best-in-class accuracy, integration, reporting and analytics. Clearwater’s cloud-based software streamlines investment accounting, freeing clients to focus on higher value activities such as asset allocation and investment selection. We moved Clearwater back into the GardenSM from the CropSM given its decision to significantly expand the size and scope of its M&A strategy. As a public company, Clearwater has yet to demonstrate the ability to successfully acquire and integrate larger scale M&A transactions. Therefore, we need to see evidence of success before considering a return to a CropSM capital campaign.

BSD Analysis:
Clearwater’s powerful data architecture and recurring SaaS model underpin strong gross margins and retention, but the shift toward larger-scale M&A introduces integration risk that could pressure near-term execution. The company trades at a growth-software multiple supported by double-digit ARR expansion, but investors will require proof of successful acquisition integration to re-rate higher. Long-term secular demand for automated investment accounting remains intact. Key risks include M&A missteps and competition from legacy vendors.

Pitch Summary:
iRhythm develops and markets the Zio, a wearable patch that monitors irregular heartbeats. Its advanced technology is well positioned for broad adoption as doctors and insurers push for earlier detection of atrial fibrillation to prevent strokes. Shares climbed after strong earnings, with 20% revenue growth and gross margins rising to 69% thanks to scaling and efficiency gains. Management also raised its forward guidance.

BSD Analysis:
iRhythm’s strong top-line acceleration and improving margins reflect growing adoption of Zio and scaling benefits in diagnostics. With reimbursement visibility improving and digital cardiology gaining traction, iRhythm supports a premium valuation. The company’s recurring-revenue model and clinical differentiation provide durable competitive advantages. Key risks include regulatory scrutiny and competition in cardiac monitoring.

Pitch Summary:
MACOM designs and manufactures high-performance semiconductors. The company has been taking steps to accelerate top-line growth and expand margins by addressing smaller, long-duration product cycle markets in which it can provide a differentiated offering, especially in compound semis (those made from two or more elements). Demand remains strong across MACOM’s key end markets, including US and European defense, data center and even telecom—spanning both long-haul and satellite segments. Moreover, MACOM’s above-average semiconductor production footprint within the US likely reduces its exposure to potential industrywide disruptions related to any potential tariff risks.

BSD Analysis:
MACOM benefits from accelerating demand across defense, data-center and telecom markets, positioning it as a differentiated supplier in compound semiconductors. Its U.S.-based footprint mitigates geopolitical and tariff risks, supporting more stable margins. With increasing exposure to long-cycle markets, revenue visibility is improving, and MACOM trades at a reasonable EV/EBITDA relative to secular semiconductor peers. Continued design wins and margin expansion are likely catalysts. Key risks include supply-chain timing and sector cyclicality.

Pitch Summary:
Flex provides outsourced electronic manufacturing services to a diverse set of end markets. The company hired a new CEO in 2020, who has been driving a strategic pivot toward manufacturing high-growth, low-volume and high-value products in areas such as health care, industrial, automotive and cloud infrastructure. Today, these higher value items account for ~60% of revenues and continue to tick higher. We believe moving away from more cyclical consumer electronics markets toward secular growth areas, such as electric vehicles and medical devices, along with the nearshoring of supply chains, will lead to faster growth and higher margins. At the beginning of the quarter, there were concerns about a potential slowdown in the industrial economy and its implications for Flex’s profit cycle. However, when the company reported its Q4 2024 earnings, it became evident that overall demand remained strong. While some end markets showed signs of weakness, these were more than offset by strength in other areas. Additionally, Flex noted increased interest from both existing and new customers regarding available capacity, as businesses work to become nimbler in an increasingly uncertain tariff environment.

BSD Analysis:
Flex is the EMS giant evolving from low-margin assembly into a diversified, design-rich manufacturing partner in automotive, cloud, healthcare, and industrial tech. Its exposure to EV components, data-center hardware, and medical devices gives it far better resilience than classic contract manufacturers. Flex’s discipline, strong FCF, and portfolio focus (plus the Nextracker spin) show a company shifting into higher-value engineering services. This is a manufacturing infrastructure play tied to real secular growth.

Pitch Summary:
Chemed (CHE), engages in the provision of healthcare and maintenance services operating through two segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of health care providers, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The stock declined due to concerns surrounding the potential Medicare cap limits proposed in current legislation for its VITAS segment alongside weaker residential demand for its plumbing services segment. We continue to maintain our position, as we believe the slowing demand in the Roto-Rooter segment is transitory and the secular demand for hospice care remains strong.

BSD Analysis:
Chemed is the oddball two-headed monster that quietly outperforms entire sectors. VITAS dominates U.S. hospice care with unmatched scale, deep clinical capabilities, and the regulatory sophistication smaller operators simply can’t replicate — and demand is locked in by demographics, not macro swings. Meanwhile, Roto-Rooter is a recession-proof cash cannon: pipes don’t care about interest rates, and homeowners call now, not “when budgets improve.” Together, the businesses create a diversified, high-margin, high-recurrence cash flow profile that almost no mid-cap can match. Management is disciplined, capital allocation is consistently excellent, and Chemed’s long-term record of compounding is borderline elite. The market keeps scratching its head at the conglomerate structure — but the numbers speak for themselves. Chemed is quietly one of the most reliable compounders in healthcare and home services.

Pitch Summary:
Chemed (CHE), engages in the provision of healthcare and maintenance services operating through two segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of health care providers, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The stock declined due to concerns surrounding the potential Medicare cap limits proposed in current legislation for its VITAS segment alongside weaker residential demand for its plumbing services segment. We continue to maintain our position, as we believe the slowing demand in the Roto-Rooter segment is transitory and the secular demand for hospice care remains strong.

BSD Analysis:
Chemed is a strange beast: part hospice powerhouse (VITAS), part plumbing and restoration royalty (Roto-Rooter) — and both are quietly excellent businesses. Hospice demand grows as the population ages and care shifts from hospitals to lower-cost settings, and VITAS has scale and clinical depth that smaller operators lack. Roto-Rooter, meanwhile, is an all-weather cash machine — when something breaks, people don’t “wait for macro to improve,” they just pay. The portfolio looks odd, but the cash-flow profile is outstanding: recurring, diversified, and recession-resistant. Management has historically been disciplined in capital allocation and buybacks. Chemed is the kind of name you own for a decade and forget about — until you notice how much it compounded.

Pitch Summary:
Founded in 2009 and headquartered in San Francisco, California, Uber is a global technology platform that facilitates the movement of people, goods and services across a wide range of markets. What began as a simple ride-hailing app has evolved into a multi-segment leader operating in more than 70 countries, connecting millions of consumers, drivers, couriers and merchants worldwide. Uber’s operations are organized into three primary business segments: Mobility, which includes ridesharing, car rentals and other personal transportation services (~45% of revenue); Delivery, which spans food, grocery, convenience and retail delivery through the Uber Eats platform (~50%); and Freight, its digital brokerage and logistics arm (~5%). These segments are built on a shared platform supported by real-time matching technology, global app penetration, strong network effects and one of the most recognized consumer brands globally—reflected in the familiar phrase, “I’ll call an Uber.” Some of the quality characteristics we have identified for Uber include: global scale and platform efficiency; an integrated, cross-segment ecosystem—where offerings like Uber One memberships drive customer activity and loyalty; and market leadership across core categories, including approximately 70% market share in U.S. ridesharing, a strong #2 position in U.S. delivery, and leading positions in key international delivery markets. Uber has scaled to sustainably FREE cash flow with continued progress on margin expansion driven by scale and disciplined cost control. Catalysts we have identified include: increased profitability as cross-promotion deepens user engagement; partnerships with taxi fleets, travel platforms and autonomous vehicle companies; and continued expansion in non-urban markets with features like Uber Reserve.

BSD Analysis:
Uber finally did the unthinkable: it became a real business with real free cash flow instead of a perpetual “growth at any cost” experiment. Mobility is humming, delivery is sticky post-COVID, and the company’s advertising and membership layers are starting to matter. Network density gives Uber a moat in both driver supply and customer convenience that would cost competitors billions to replicate. Regulatory headaches never fully go away, but Uber has proven it can adapt and still expand margins. With fixed costs leveraged and capital discipline now embedded, incremental revenue drops through at a rate early investors only dreamed about. This is a dominant urban-transport infrastructure play, not just an app on your phone.

Pitch Summary:
Alcon, a global leader in eye care, was one of the largest detractors during the quarter. Aside from its earnings report, there was little material news, and we did not view anything in the report as affecting the company’s long-term fundamentals. While quarterly updates can influence sentiment, our focus remains on the strength and quality of the business. Alcon operates in a resilient, oligopolistic industry with high barriers to entry and recurring revenue streams tied to its large installed base of cataract surgery systems. It also continues to innovate across product categories, including its premium intraocular lens portfolio (e.g., PanOptix, Vivity), ultra-premium daily contact lenses (e.g., Dailies Total1) and over-the-counter products, such as Systane for dry eyes. Since its spinoff from Novartis in 2019, the company has also demonstrated greater agility in R&D, commercial execution and capital allocation—catalysts we previously identified. More broadly, we believe Alcon’s ability to strengthen its partnerships with eye care professionals and broaden access to underutilized premium technologies makes the company uniquely positioned to benefit from an aging population, increased access to eye care in emerging markets, and rising awareness and diagnosis of chronic dry eye conditions.

BSD Analysis:
Alcon is the quiet medtech powerhouse riding one of the most reliable demographic megatrends on the planet: aging eyes. Cataract procedures keep growing, premium intraocular lenses are taking share, and Alcon owns the surgical suite with an installed base competitors can’t realistically displace. Its vision-care segment adds a sticky, high-margin consumer layer that hums regardless of macro noise — people don’t stop buying contacts and eye drops in a recession. Margins continue expanding as post-spin execution pays off, the product pipeline is better than investors give it credit for, and Alcon’s global footprint gives it leverage in both emerging and developed markets. The market still prices this like a slow, steady medtech name, but the truth is Alcon has multiple structural tailwinds, relentless repeat revenue, and a surgical franchise with decades of runway. This is a compounding engine hiding inside a conservative multiple.

Pitch Summary:
Amgen, the biopharmaceutical company, was one of the largest detractors for the quarter. While the company’s branded drugs continued to advance (a previously identified catalyst), with cholesterol medicine Repatha, osteoporosis treatment Evenity and bone-strengthening drug Prolia all growing sales in the double digits, concerns surrounding potential tariff impacts, tax reform and pressure on drug prices weighed on shares. We believe it is too early to assess the full impact of these macro uncertainties and are confident in Amgen’s demonstrated ability to adapt through evolving policy and pricing dynamics. The company reaffirmed its long-term commitment to domestic manufacturing and innovation through its upcoming $2 billion expansions in Ohio and North Carolina, building on more than $5 billion in U.S. operational investments since 2017. Furthermore, Amgen continued to advance its robust pipeline, as its 1L bemarituzumab (bema) phase 3 trial for gastric cancer met its primary endpoint, and MariTide, the company’s weight-loss drug, demonstrated strong efficacy in phase 1 and 2 trials. MariTide, which could offer more convenient monthly dosing compared to daily or weekly regimens, showed promising early results, though tolerability will be an important focus heading into phase 3. Management noted that modified dose ramp-up strategies may help mitigate these effects. Despite near-term pressures, we remain encouraged by Amgen’s continued market share gains across key therapies and the potential to enhance the company’s competitiveness and resilience in a dynamic healthcare landscape.

BSD Analysis:
Amgen is the large-cap biotech that morphed from a couple of blockbuster cash cows into a diversified, innovation-forward platform with genuine pipeline depth. Legacy drugs still throw off tons of cash, but newer assets in oncology, inflammation, and rare disease are increasingly doing the heavy lifting. The Horizon acquisition beefed up the rare disease portfolio and expanded Amgen’s specialty footprint. Biosimilars add an interesting, steady growth leg most big pharmas don’t fully enjoy. The balance sheet can handle deals, the dividend is solid, and management has been more disciplined than peers on both price and risk. You’re basically getting a pharma-biotech hybrid that still isn’t priced like a top-tier pipeline story.

Pitch Summary:
Microchip Technology, the microcontroller (MCU) and analog semiconductor producer, was a top contributor for the quarter. After several quarters of underperformance driven by prolonged customer destocking, the company’s fundamentals began to improve meaningfully, as returning CEO Steve Sanghi’s turnaround plan is underway. Bookings showed signs of stabilization, supported by more balanced inventories across customers and distribution channels, as well as indications of recovering end-market demand. Operational execution also improved under the renewed leadership, with early benefits emerging from cost-saving initiatives—such as the closure of its Arizona wafer fabrication facility—and tighter inventory management. Microchip’s long-standing customer relationships and commitment to extended product lifecycles continue to support recurring revenue and reduce design-in risk. Combined with its consistent record of strong FREE cash flow generation and shareholder returns, this disciplined approach reinforces our conviction in the company’s ability to manage through industry cycles. Longer term, we believe Microchip remains well-positioned to gain share in 16- and 32-bit MCUs and areas including IoT, 5G infrastructure, autonomous vehicles and data centers.

BSD Analysis:
Microchip is the cash-generating microcontroller and analog beast riding the slow, grinding digitization of everything — autos, industry, aerospace, and IoT. Its end markets aren’t flashy, but they’re sticky and product lifecycles are measured in decades. That means design wins turn into long-lived, high-margin annuities. The recent downturn and inventory correction are cyclical noise in a structurally growing content story. Microchip’s capital allocation — de-lever, dividends, buybacks — is shareholder-friendly without starving R&D. When the cycle turns, the operating leverage here is bigger than the sleepy ticker suggests.

Pitch Summary:
Microsoft, the global leader in software and enterprise services, was the top contributor for the quarter. The company delivered a strong quarterly update, with Azure revenue growing 35%—well ahead of expectations—driven by improved execution in core cloud services and sustained AI-related demand. Importantly, strength extended beyond AI, with renewed momentum in traditional enterprise cloud workloads, such as data platforms, infrastructure hosting and developer services. Profitability also impressed, with operating margins expanding to 46% supported by disciplined cost control. While near-term results were strong, our conviction remains grounded on Microsoft’s enduring advantages: dominant positions in mission-critical software, high recurring revenue driven by a deep subscriber base, and the ability to reinvest at scale. One example is GitHub Copilot—a generative AI tool that helps developers write, review and debug code—which now has over 15 million users and is seeing increasing enterprise adoption. With widespread use of offerings like Copilot, Teams and LinkedIn, and underpinned by robust FREE cash flow supporting continued innovation, we believe Microsoft remains exceptionally well-positioned to compound value across cloud, productivity and AI-enabled workflows over the long term.

BSD Analysis:
Microsoft has essentially put a tollbooth on enterprise AI adoption: if you’re a corporate CIO, the default answer is “we’ll just do it inside Microsoft.” Azure, Copilot, GitHub, Security — every layer monetizes AI in a way that compounds across the stack. The company’s distribution advantage is absurd: it can light up new AI features across millions of users with one SKU decision. Meanwhile, core businesses like Office and Windows keep generating monster free cash flow to fund the AI arms race. The balance sheet is pristine, buybacks are relentless, and switching costs are effectively career risk for IT leaders. Microsoft doesn’t need to win every AI narrative battle — it’s already won the seat at the enterprise table.

Pitch Summary:
Safran, the French aerospace propulsion and equipment manufacturer, was a top contributor during the quarter. The company continues to demonstrate high-quality characteristics—namely durable aftermarket revenue, strong pricing power and long-standing customer relationships across its propulsion, avionics and interiors franchises. Record 2024 results carried into 2025, supported by strong air traffic recovery, particularly in Asia, and increased aircraft utilization. As the dominant supplier of narrow-body aircraft engines (approximately 70% market share), Safran benefits from rising demand for required maintenance as airlines extend the lives of aging fleets. With roughly one-fifth of its revenues tied to defense, the company also stands to gain from rising European defense budgets, where policymakers are placing increased emphasis on sourcing from regional suppliers. We also continue to view the transition from the legacy CFM56 engine to the more fuel-efficient LEAP platform as a meaningful catalyst—especially given that a large portion of the installed LEAP fleet has yet to reach its first maintenance cycle, providing a long and visible runway (pardon the pun) of profit growth. Looking ahead, we believe Safran remains well-positioned to benefit from global fleet modernization and the industry’s pivot toward more efficient and sustainable aircraft platforms.

BSD Analysis:
Safran is one half of the duopoly that powers most of the world’s narrow-body fleet — CFM engines — and that alone gives it a multi-decade revenue stream. The post-COVID air traffic recovery, plus an aging fleet needing more efficient engines, gives Safran visibility that most industrials would kill for. Its aftermarket business is a high-margin machine as more engines need maintenance and overhauls. On top of that, Safran has serious exposure to avionics and defense, which add both resilience and upside as global budgets rise. Temporary supply-chain issues are noise compared to the structural air travel and defense tailwinds. This is a premium aerospace compounder still not fully priced like one.

Pitch Summary:
LVMH Moët Hennessy Louis Vuitton, the global leader in luxury goods, was one of the largest detractors for the quarter. While the luxury goods industry is experiencing a cyclical slowdown, we believe LVMH’s fundamentals remain sound. The company continues to demonstrate long-term brand stewardship, integrating global maisons at scale while preserving their creative autonomy. Although Dior—responsible for 16% of group profits—underperformed in 2024 due to pricing fatigue and softer product innovation, LVMH responded decisively by naming Jonathan Anderson, the designer credited with revitalizing Loewe, as Dior’s new creative director. Despite mixed macro demand, other brands such as Sephora, Loewe and Tiffany reported strong growth, underscoring the breadth and durability of the group’s diversified portfolio. Operating margins declined modestly, as management chose to preserve brand equity and marketing investment rather than cut costs into weakness. Free cash flow improved year-over-year, and the company ended 2024 with €10 billion in cash, highlighting its strong and flexible balance sheet. As Asian demand stabilizes and innovation pipelines refresh, we believe LVMH’s scale, vertical integration and revitalized creative leadership will drive its success in the long run.

BSD Analysis:
LVMH is the final boss of global luxury — portfolios of brands so powerful they bend consumer behavior and pricing to their will. Short-term noise around China or aspirational shoppers doesn’t change the long-term math: ultra-high-net-worth consumers are expanding, and LVMH owns their closets, cellars, and suitcases. Vertical integration, tight control of distribution, and ruthless brand management keep competitors permanently on the back foot. Its balance sheet is a fortress, cash generation is enormous, and management has a long track record of buying great assets and making them better. This isn’t a fashion stock; it’s a luxury monopoly with multi-decade duration. The market regularly forgets that — and then remembers in a hurry.